Relay Therapeutics (NASDAQ:RLAY - Get Free Report) is scheduled to post its quarterly earnings results after the market closes on Thursday, May 2nd. Analysts expect Relay Therapeutics to post earnings of ($0.70) per share for the quarter.
Relay Therapeutics (NASDAQ:RLAY - Get Free Report) last released its earnings results on Thursday, February 22nd. The company reported ($0.67) EPS for the quarter, beating the consensus estimate of ($0.76) by $0.09. Relay Therapeutics had a negative net margin of 1,263.49% and a negative return on equity of 42.43%. During the same quarter in the previous year, the business posted ($0.56) EPS. On average, analysts expect Relay Therapeutics to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.
Relay Therapeutics Stock Up 3.5 %
Relay Therapeutics stock traded up $0.21 during trading hours on Friday, hitting $6.37. 769,750 shares of the company traded hands, compared to its average volume of 1,148,461. The firm has a market cap of $843.01 million, a P/E ratio of -2.28 and a beta of 1.63. The firm's 50-day simple moving average is $8.24 and its two-hundred day simple moving average is $8.82. Relay Therapeutics has a 1-year low of $5.70 and a 1-year high of $13.32.
Wall Street Analyst Weigh In
Several research firms have commented on RLAY. Leerink Partnrs reissued an "outperform" rating on shares of Relay Therapeutics in a research note on Thursday, February 22nd. Stifel Nicolaus raised their target price on shares of Relay Therapeutics from $25.00 to $30.00 and gave the company a "buy" rating in a research note on Thursday, February 22nd. Five analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus target price of $26.00.
Check Out Our Latest Analysis on RLAY
About Relay Therapeutics
(
Get Free Report)
Relay Therapeutics, Inc operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors.
Further Reading
Before you consider Relay Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Relay Therapeutics wasn't on the list.
While Relay Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
